Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer.

Chen, Xiao, Hu, Ze-Ping, Yang, Xiao-Xia, Huang, Min, Gao, Yihuai, Tang, Wenbo, Chan, Sui Yung, Dai, Xihu, Ye, Jinxian, Ho, Paul Chi-Liu, Duan, Wei, Yang, Hong-Yuan, Zhu, Yi-Zhun and Zhou, Shu-Feng 2006, Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer., International immumopharmacology, vol. 6, no. 3-4, pp. 499-508, doi: 10.1016/j.intimp.2005.08.026.

Attached Files
Name Description MIMEType Size Downloads

Title Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer.
Author(s) Chen, Xiao
Hu, Ze-Ping
Yang, Xiao-Xia
Huang, Min
Gao, Yihuai
Tang, Wenbo
Chan, Sui Yung
Dai, Xihu
Ye, Jinxian
Ho, Paul Chi-Liu
Duan, WeiORCID iD for Duan, Wei
Yang, Hong-Yuan
Zhu, Yi-Zhun
Zhou, Shu-Feng
Journal name International immumopharmacology
Volume number 6
Issue number 3-4
Start page 499
End page 508
Publisher Elsevier Ltd
Place of publication Barking, England
Publication date 2006-03
ISSN 1567-5769
Keyword(s) Ganoderma lucidum
Immune functions
Summary Many herbal medicines are widely used as immuno-modulators in Asian countries. Ganoderma lucidum (Lingzhi) is one of the most commonly used herbs in Asia and preclinical studies have established that the polysaccharide fractions of G. lucidum have potent immuno-modulating effects. However, clinical evidence for this is scanty. The present open-labeled study aimed to evaluate the effects of G. lucidum polysaccharides on selected immune functions in patients with advanced colorectal cancer. Forty-seven patients were enrolled and treated with oral G. lucidum at 5.4 g/day for 12 weeks. Selected immune parameters were monitored using various immunological methods throughout the study. In 41 assessable cancer patients, treatment with G. lucidum tended to increase mitogenic reactivity to phytohemagglutinin, counts of CD3, CD4, CD8 and CD56 lymphocytes, plasma concentrations of interleukin (IL)-2, IL-6 and interferon (IFN)-γ, and NK activity, whereas plasma concentrations of IL-1 and tumor necrosis factor (TNF)-α were decreased. For all of these parameters, no statistical significance was observed when a comparison was conducted between baseline and those values after a 12-week treatment with G. lucidum. The changes of IL-1 were correlated with those for IL-6, IFN-γ, CD3, CD4, CD8 and NK activity (p < 0.05) and IL-2 changes were correlated with those for IL-6, CD8 and NK activity. The results indicate that G. lucidum may have potential immuno-modulating effect in patients with advanced colorectal cancer. Further studies are needed to explore the benefits and safety of G. lucidum in cancer patients.
Language eng
DOI 10.1016/j.intimp.2005.08.026
Field of Research 111502 Clinical Pharmacology and Therapeutics
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2005, Elsevier B.V.
Persistent URL

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 67 times in TR Web of Science
Scopus Citation Count Cited 78 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 1045 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Mon, 13 Oct 2008, 15:53:03 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact